Kentucky Cabinet for Economic Development to Partner With BioNeutral in Pursuit of the Company's Growth in Kentucky

NEWARK, N.J., Jan. 4, 2011 /PRNewswire/ -- BioNeutral Group, Inc. (OTC Bulletin Board: BONU), a specialty life science technology-based company, today announced it has received a commitment of support from the Commissioner of Kentucky's Department for Business Development (the Department).

The Department's mandate includes exploring innovative ways to stimulate Kentucky's economy by supporting existing businesses and attracting new enterprises in Kentucky at the lowest overall cost of doing business.

Acknowledging BioNeutral's innovative approach and product offerings in the areas of life sciences, the Department has offered their full support for the establishment of BioNeutral's operations in Kentucky. This includes identifying, and in some cases providing, the necessary facilities, workforce, training and financial resources and incentives to initiate and grow the business. In becoming the single point of contact for BioNeutral in establishing operations and achieving growth in Kentucky, the Department will facilitate growth by providing financial incentives, assisting to foster a productive workforce and ultimately enabling a business climate that leads to prosperity.

"Following a series of productive meetings in Kentucky," said Stephen J. Browand, CEO of BioNeutral, "We are extremely pleased to be building momentum and moving forward with our plans. The offer from Kentucky's Cabinet for Economic Development is precisely the kind of partnership and support that will enable us to succeed."

For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutralgroup.com.  

About The Kentucky Cabinet for Economic Development

The Cabinet for Economic Development is the primary state agency in Kentucky responsible for creating new jobs and investment in the state. Programs administered by the Cabinet are designed to support and promote economic development within the state, primarily by attracting new industries to the state, assisting in the development of existing industries, and assisting communities in preparing for economic development opportunities.

By statute, the Cabinet is governed by the Kentucky Economic Development Partnership (Partnership Board). The Partnership Board is responsible for directing and overseeing the Cabinet and adopting a Strategic Plan. The Kentucky Economic Development Finance Authority (KEDFA) is a statutorily created committee under the authority of the Partnership Board. KEDFA is responsible for awarding most of the financial incentives offered by the Cabinet. For more information please visit http://www.thinkkentucky.com.

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a specialty technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene™ and Ogiene™, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene™ brand have been submitted to the EPA for approval for sale in the United States and has already been approved for sale in Germany and is permitted to be sold in the UK, France and Sweden. AutoNeutral is a Registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutralgroup.com.  

Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393

Follow us on Twitter: http://twitter.com/bioneutralgroup

Forward-Looking Statements

This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.

SOURCE BioNeutral Group, Inc.